Text size :

Rare diseases, supplements and nutraceuticals: “Clinicians demand more scientific evidence”

ADNKRONOS

November 5, 2026

Rome, Nov 5. (Adnkronos Health) – Uniamo Italian Federation for Rare Diseases – in collaboration with ApertaMente – today publishes the results of the second survey by the Nutraceuticals and Rare Diseases Observatory (Nura), conducted among clinicians on the prescription and use of food supplements and nutraceuticals in people with rare diseases. The Report – a note informs – integrates the framework initiated with a similar survey conducted on patients and caregivers and allows for the first time to compare the two perspectives. The survey – an anonymous online questionnaire – collected 94 responses from clinicians from various specialist areas across the national territory, of which 59 complete questionnaires were used for analysis. It reveals a present but cautious use in clinical practice: only 26% of clinicians state that they often or always suggest or prescribe supplements, while about 70% do so occasionally or rarely. The use is linked to specific needs, such as nutritional deficiencies, metabolic support, and asthenia, and rarely for preventive purposes or general well-being. Only 10.6% of clinicians believe that these products do not have significant value. Choices are guided by available scientific evidence, composition and dosages, and safety. But evidence is lacking: for 38.3% of clinicians, the lack of robust studies is the main critical issue. Added to this are costs, often borne by the patient, and the difficulty in measuring efficacy. Over 60% of doctors often or always receive requests for clarification from patients.

The comparison with the data from the first edition, collected from 557 patients and caregivers (261 complete questionnaires), shows how the two points of view are quite coincident. Despite different and non-overlapping samples, the numbers show a clear indication oriented towards the need for uniform regulation. Regarding use, over 80% of patients stated they took supplements, in 59% of cases three or more products together, and in 77% for over 12 months. Regarding efficacy, 75.6% said they were satisfied or very satisfied, but in contrast, clinicians demand evidence that is not currently available. Regarding information, 94% of patients informed themselves independently, especially online, and only 13.8% turned to associations or general practitioners, a fact that confirms the difficulty for clinicians in relying on validated studies. The two surveys also converge on costs, and especially on safety. In 2024, the cost was borne by the patient in 74.4% of cases, with an average annual expenditure of 612 euros on the first three supplements, and one in five patients did not communicate their use to their doctor. Clinicians specifically indicate the cost borne by the patient as an obstacle to appropriate use and equitable access. Also on the regulatory framework, the two samples describe the same ‘grey area’: products used for clinical purposes but regulated as simple food supplements.

“Three years ago, we began collecting data on a topic not yet sufficiently investigated, at least from our point of view: nutraceuticals and food supplements – stated Annalisa Scopinaro, president of Uniamo -. With the support of the scientific committee, composed of clinicians, statisticians, and experts in health system economics and management, we launched two specific surveys. After patients and clinicians, the next step will be to turn to Institutions, to understand if and how this phenomenon is addressed and potentially regulated.” Three priorities emerge from the comparison: bringing experience and evidence closer with observational studies and real-world evidence, strengthening qualified and independent information for clinicians and patients, and defining minimum quality, safety, and traceability criteria for products used in vulnerable populations. After patients and clinicians, the third edition will focus on the regional level with a precise question: how do the Regions address this issue today? The questionnaire will be disseminated in the coming weeks as a collaborative reconnaissance, with the aim of building shared standards and arriving at a defined framework (patients, clinicians, institutions) that can provide a definition of the priorities to be addressed in this area. An area where uncertainty and a lack of regulation seem to persist.

Jiji Press

Related

Page TOP